| Nasdaq: IMMU
Immunomedics, Inc. is a biopharmaceutical company, which engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. Immunomedics was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.